The preclinical profile of lurasidone: clinical relevance for the treatment of schizophrenia.

@article{Tarazi2013ThePP,
  title={The preclinical profile of lurasidone: clinical relevance for the treatment of schizophrenia.},
  author={Frank I Tarazi and Marco Andrea Riva},
  journal={Expert opinion on drug discovery},
  year={2013},
  volume={8 10},
  pages={1297-307}
}
INTRODUCTION Lurasidone is a novel antipsychotic drug approved for the treatment of schizophrenia in adults. It is formulated into tablets, administered orally once/day (dose range 40-160 mg/day) does not require titration, but needs to be given with food to maximize its plasma exposure. AREAS COVERED This review focuses on the preclinical discovery of lurasidone. Furthermore, the article provides analysis on the pharmacological, behavioral and molecular mechanisms of lurasidone and their… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-9 of 9 extracted citations

Similar Papers

Loading similar papers…